Ingo Mellinghoff News Today

Saving Spots is an initiative that protects leopards in Zambia while ensuring the cultural traditions of the Lozi people stay intact.

Scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.

The oral drug vorasidenib nearly tripled progression-free survival in patients with grade 2 gliomas compared to placebo, nearly 28 months versus 11 months, according to a recent study.

A new experimental drug therapy has shown some promising signs of slowing down the progression of a type ...

A targeted therapy has more than doubled progression-free survival of patients with gliomas — a disease that killed Spanish golf player Severiano Ballesteros

In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening.

MONDAY, June 5, 2023 (HealthDay News) -- An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds.

Vorasidenib reduced the risk of disease progression or death for certain patients with low-grade brain cancer, recent study results showed.

In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.

Treatment with the IDH1/2 inhibitor vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma, according to findings from the phase 3, double-blind INDIGO trial.